Description de l'entreprise
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
Conseil d'administration & Conseil de surveillance
| PDG |
| Christopher A. Viehbacher |
| Conseil d'administration |
| Michael McDonnell, Dr. Ginger Gregory, Rachid Izzar, Susan H. Alexander, Nicole Murphy, Priya Singhal |
| Conseil de surveillance |
| Caroline Dorsa, Eric K. Rowinsky, Jesus B. Mantas, Maria C. Freire, Stephen A. Sherwin, William A. Hawkins, Susan Langer, Christopher A. Viehbacher, Lloyd B. Minor |
Données de l'entreprise
| Nom: |
Biogen Inc. |
| Adresse: |
225 Binney Street,Cambridge, Massachusetts 02142, USA |
| Téléphone: |
+1 781-464-2000 |
| Fax: |
+1-617-679-2617 |
| Courriel: |
-
|
| Internet: |
www.biogen.com |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
72.20% |
| IPO date: |
- |
Relations avec les investisseurs
| Nom: |
Karen Jewell |
| Téléphone IR: |
781-464-2442 |
| IR-Fax: |
- |
| E-mail IR: |
IR@biogenidec.com
|
